Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study uses 3D scans to track jaw bone damage from common osteoporosis drugs

NCT ID NCT07588269

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will look at how jaw bone quality changes over time in patients with medication-related osteonecrosis of the jaw (MRONJ), a side effect of drugs like bisphosphonates. Researchers will analyze existing CBCT scans from 25 adults to measure bone density and structure at diagnosis and during follow-up. The goal is to better understand the disease and improve future management.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better predict and manage jaw bone damage in patients taking bone-strengthening medications.
What could go wrong
This is a small, retrospective study (25 people) that only looks at existing scans, so it cannot prove new treatments or directly benefit participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2027

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with medication-related osteonecrosis of the jaw identified retrospectively from clinical and imaging records at participating French hospital centers, including CHU de Nantes, Centre Léon Bérard, CHU de Nancy/Centre Oscar Lambret, and AP-HP Pitié-Salpêtrière.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient aged 18 years or older * Diagnosis of medication-related osteonecrosis of the jaw (MRONJ), stage 0, 1, or 2 * Available diagnostic CBCT and at least 2 follow-up cone beam computed tomography (CBCT) examinations * Able to understand the study information and not opposed to participation Exclusion Criteria: * Other jaw bone disease * History of cervicofacial irradiation * Stage 3 medication-related osteonecrosis of the jaw * Fewer than 2 follow-up cone beam computed tomography (CBCT) examinations

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medication-related osteonecrosis of the jaw are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteonecrosis of the jaw

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medication-related osteonecrosis of the jaw Osteonecrosis of the jaw

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.